Fabre-Kramer Pharmaceuticals

{{primary sources|date=August 2016}}

{{Infobox company

| name = Fabre-Kramer Pharmaceuticals

| logo = Fabre-Kramer Pharmaceuticals Logo.jpg

| logo_size =

| logo_alt =

| logo_caption =

| logo_padding =

| image =

| image_size =

| image_alt =

| image_caption =

| native_name =

| native_name_lang =

| former_name =

| type = S Corporation

| industry = Pharmaceuticals

| founded = 1992

| founder =

| hq_location = Houston, Texas

| hq_location_city =

| hq_location_country =

| area_served =

| key_people = Stephen Kramer (CEO)

Ed Koehler (Executive Vice President, CFO)

| products = Travivo (Gepirone ER), FKB01MD, FKW00GA, FKF02SC, FKK01PD

| brands =

| services =

| owner =

| ratio =

| rating =

| website = [https://www.fabrekramer.com www.fabrekramer.com]

}}

Fabre-Kramer Pharmaceuticals is a pharmaceutical company that specializes in the development of psychotropic drugs. Products in their current development pipeline include gepirone and FKB01MD for major depression, gepirone and FKW00GA for social anxiety disorder,{{Cite web |title=Pipeline – Fabre-Kramer Pharmaceuticals, Inc. |url=https://fabrekramer.com/pipeline/ |archive-url=https://web.archive.org/web/20230330232143/https://fabrekramer.com/pipeline/ |archive-date=March 30, 2023 |access-date=2023-03-30 |language=en}} gepirone for hypoactive sexual desire disorder, FKF02SC for schizophrenia, and FKK01PD for Parkinson's disease.{{cite web |url=http://www.fabrekramer.com/products.html |title=Product Pipeline |publisher=Fabre Kramer Pharmaceuticals |accessdate=2011-10-16 |url-status=dead |archiveurl=https://web.archive.org/web/20111111164303/http://www.fabrekramer.com/products.html |archivedate=2011-11-11 }}

The company has also conducted clinical studies on a gepirone extended release formulation for major depression.{{cite journal | vauthors = Fabre LF, Smith LC | title = The Effect of Major Depression on Sexual Function in Women | journal = J Sex Med | volume = 9| issue = 1| pages = 231–9|date=August 2011 | pmid = 21883948 | doi = 10.1111/j.1743-6109.2011.02445.x }}{{cite journal | vauthors = Fabre LF, Smith LC, DeRogatis LR | title = Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain--a post hoc analysis | journal = J Sex Med | volume = 8 | issue = 9 | pages = 2569–81 |date=September 2011 | pmid = 21707926 | doi = 10.1111/j.1743-6109.2011.02330.x }}{{cite journal | vauthors = Fabre LF, Brown CS, Smith LC, Derogatis LR | title = Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women | journal = J Sex Med | volume = 8 | issue = 5 | pages = 1411–9 |date=May 2011 | pmid = 21324094 | doi = 10.1111/j.1743-6109.2011.02216.x }}

In 2007, Fabre-Kramer Pharmaceuticals along with GlaxoSmithKline (GSK) received a 'not approvable' letter from the US Food and Drug Administration, for a gepirone extended release drug, an antidepressant treatment for adults.{{Cite web |last=Lewcock |first=Anna |date=November 5, 2007 |title=GSK, Fabre-Kramer lose out on antidepressant |url=https://www.outsourcing-pharma.com/Article/2007/11/05/GSK-Fabre-Kramer-lose-out-on-antidepressant |url-status=live |archive-url=https://web.archive.org/web/20230910224559/https://www.outsourcing-pharma.com/Article/2007/11/05/GSK-Fabre-Kramer-lose-out-on-antidepressant |archive-date=September 10, 2023 |access-date=2020-05-11 |website=outsourcing-pharma.com |language=en-GB}}